Sheffield, UK, September 2024: SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the appointment of Mike Daniels as Chief Commercial Officer. Mike will focus on development of SynGenSys’ commercial product offering, delivering the Company’s portfolio of synthetic promoter systems to market.
Mike has over 25 years’ experience in commercial product development from across the life science sector, including leadership roles at GE Healthcare, Thermo Fisher Scientific, Cancer Research UK, Promega, and Evonetix Ltd. He has a PhD from the Department of Biochemistry and Genetics at the University of Newcastle, as well as numerous professional qualifications in marketing, management, and IP law.
Professor David James, co-founder and Chief Technology Officer of SynGenSys, commented: “We are thrilled to welcome Mike to SynGenSys, reflecting the ongoing development of our team. His extensive experience will help drive the translation of our technology and expertise through commercialisation, and build awareness of our synthetic promoter offerings with customers worldwide.”
Dr Mike Daniels, Chief Commercial Officer at SynGenSys said: “SynGenSys’ unique expertise in gene expression systems is enabling a step change in the efficiency of biopharmaceutical production and provides critical capabilities in tissue specific expression for gene therapy applications, enhancing both safety and efficacy. Working with the extraordinary team at SynGenSys is an immense privilege, and I look forward to delivering their solutions to customers across these exciting fields.”
